Kliniske studier for HIV i Houston, TX
17 studier for HIV søker deltakere på steder i og rundt Houston (innen ca. 30 miles). Åpne et studie for å se hvem som kan delta og hvordan du kontakter studieteamet.
Offisiell studietekst (engelsk)
Rekrutterer til et studie her? Få det fremtredende øverst på siden – $99 i 30 dager →
Implementation Study of Lenacapavir Pre-exposure Prophylaxis for HIV Prevention
RekruttererObservasjonsstudie
- UT Health, Houston
- Thomas Street at Quentin Mease Health Center, Houston
A Study to Investigate Cabotegravir Ultra Long-Acting (CAB ULA) Plus Rilpivirine Ultra Long-Acting (RPV ULA) in Adults and Adolescents With HIV Who Are Virologically Suppressed
RekruttererFase 3
- GSK Investigational Site, Houston
ADELANTE: A Randomized Controlled Trial to Improve Engagement in Care for Latinos With HIV
Rekrutterer
- Baylor College of Medicine, Houston
A Clinical Study of Islatravir and Ulonivirine for People With HIV-1 Who Have Not Been Treated Before (MK-8591B-062)
RekruttererFase 2/3
- Saint Hope Foundation, Inc. ( Site 1504), Bellaire · 7 mi unna
Very Early Intensive Treatment of Infants Living With HIV to Achieve HIV Remission
RekruttererFase 1/2
- 5128, Baylor College of Medicine/Texas Children's Hospital Clinical Research Site, Houston
Cytotoxic T Lymphocytes in Treating Patients With Malignancies With BK and/or JC Virus
RekruttererFase 2
- M D Anderson Cancer Center, Houston
A Clinical Trial to Look at the Safety and Immune Responses of the RNA-based Vaccine BNT168 in Adults Living With or Without HIV
RekruttererFase 1Frivillige helsepersonell ønskes velkommen
- The Crofoot Research Center, Houston
Impact of Behavior Modification Interventions and Lung Cancer Screening on Smoking Cessation in People Living With HIV: A Feasibility Study
Rekrutterer
- University of Texas M.D. Anderson Cancer Center, Houston
Positive Peers Intervention Clinical Trial
Rekrutterer
- Thomas Street Clinic, Houston
Screen2Prevent (S2P)
RekruttererFrivillige helsepersonell ønskes velkommen
- Baylor College of Medicine, Houston
A Study to Evaluate the Use of Resmetirom in Participants With MASLD and HIV
RekruttererFase 2
- UT Health Houston, Houston
A Phase 2b Study Evaluating Oral VH4524184 Regimens in Treatment Naïve Persons With HIV-1 (INNOVATE Study)
RekruttererFase 2
- GSK Investigational Site, Houston
- GSK Investigational Site, Houston
- GSK Investigational Site, Bellaire · 7 mi unna
Kidney Transplantation From Donors With HIV: Impact on Rejection and Long-Term Outcomes (Expanding HOPE Kidney)
Rekrutterer
- Houston Methodist Research Institute, Houston
Menopausal HT for Women Living With HIV (HoT)
RekruttererFase 4
- Houston AIDS Research Team CRS (31473), Houston
Assessing the Use of MY-RIDE, a Just-in-time Adaptive Intervention, to Improve HIV Prevention and Substance Use in Youth Experiencing Homelessness
Rekrutterer
- The University of Texas Health Science Center at Houston, Houston
Cholesterol and Inflammation Lowering Via Bempedoic Acid, an ACL-inhibiting Regimen in HIV Trial (CLEAR HIV Trial)
RekruttererFase 2
- UT Health Houston, Houston
Pharmacokinetics, Safety, Tolerability of Dolutegravir/Rilpivirine in Pediatrics
RekruttererFase 1/2
- GSK Investigational Site, Houston
- GSK Investigational Site, Houston
HIV-studier i andre byer
- Washington, DC22 studier
- New York City, NY19 studier
- Miami, FL17 studier
- Baltimore, MD16 studier
- San Francisco, CA15 studier
- Atlanta, GA14 studier
- Chicago, IL14 studier
- Boston, MA11 studier
- Philadelphia, PA11 studier
- San Diego, CA10 studier
- Los Angeles, CA9 studier
- Seattle, WA8 studier
Andre studier i Houston
- Ikke-småcellet lungekreft145 studier
- Brystkreft126 studier
- Kreft (alle typer)121 studier
- Metastatisk kreft104 studier
- Kolorektal kreft102 studier
- Eggstokkreft89 studier
- Akut myelogen leukemi85 studier
- Lungekreft78 studier
- Prostatakreft76 studier
- Endometriekreft68 studier
- Pankreaskreft61 studier
- Melanom59 studier
Fra ClinicalTrials.gov, data hentet 5. okt. 2026. Hver studie setter sine egne kvalifikasjonskrav; studieteamet avgjør hvem som kan delta.